Information Provided By: 
Fly News Breaks for April 12, 2018
BLCM
Apr 12, 2018 | 07:59 EDT
Cantor Fitzgerald analyst Elemer Piros raised his price target for Bellicum Pharmaceuticals to $18 following the announcement of the FDA's lift of its U.S. clinical hold for BPX-501. The analyst now has increased confidence across the BPX-501 platform. He reiterates an Overweight rating on the shares.
News For BLCM From the Last 2 Days
There are no results for your query BLCM
